ipscell.com
Will Right-To-Try Morph into Right-To-Profit for Stem Cell Clinics? - The Niche
On one level a reasonable argument can be made for letting terminally ill patients have a right to try experimental as yet unproven therapies, but in the real world Right-To-Try laws have many downsides. On the whole, they are likely to be negative for patients as a group. Raising the stakes is a push for … Will Right-To-Try Morph into Right-To-Profit for Stem Cell Clinics? Read More »
Professor Paul Knoepfler, Ph.D.